California Public Employees Retirement System decreased its position in Haemonetics Co. (NYSE:HAE) by 2.5% during the 4th quarter, Holdings Channel reports. The firm owned 98,035 shares of the medical instruments supplier’s stock after selling 2,523 shares during the quarter. California Public Employees Retirement System’s holdings in Haemonetics were worth $5,694,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of HAE. Crossmark Global Holdings Inc. bought a new stake in shares of Haemonetics in the 3rd quarter worth about $442,000. American Century Companies Inc. grew its holdings in shares of Haemonetics by 7.4% in the 3rd quarter. American Century Companies Inc. now owns 49,704 shares of the medical instruments supplier’s stock worth $2,230,000 after purchasing an additional 3,433 shares during the last quarter. Prudential Financial Inc. grew its holdings in shares of Haemonetics by 1.8% in the 3rd quarter. Prudential Financial Inc. now owns 90,892 shares of the medical instruments supplier’s stock worth $4,078,000 after purchasing an additional 1,600 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Haemonetics by 53.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 27,603 shares of the medical instruments supplier’s stock worth $1,239,000 after purchasing an additional 9,607 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan grew its holdings in shares of Haemonetics by 59.7% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 19,800 shares of the medical instruments supplier’s stock worth $888,000 after purchasing an additional 7,400 shares during the last quarter. 98.12% of the stock is currently owned by institutional investors and hedge funds.
In other Haemonetics news, Director Mark W. Kroll sold 7,118 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $63.00, for a total transaction of $448,434.00. Following the sale, the director now owns 33,881 shares of the company’s stock, valued at approximately $2,134,503. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michelle L. Basil sold 389 shares of the stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $72.23, for a total transaction of $28,097.47. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,621 shares of company stock worth $484,766. Insiders own 1.20% of the company’s stock.
Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.18. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The firm had revenue of $234.04 million for the quarter, compared to analyst estimates of $227.79 million. During the same quarter in the prior year, the firm earned $0.43 EPS. The company’s revenue was up 2.7% on a year-over-year basis. equities analysts forecast that Haemonetics Co. will post 1.86 earnings per share for the current year.
Haemonetics announced that its Board of Directors has approved a share repurchase program on Tuesday, February 6th that authorizes the company to buyback $260.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
Several research firms have recently weighed in on HAE. Zacks Investment Research lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, November 20th. ValuEngine raised shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Barrington Research reaffirmed an “outperform” rating and issued a $71.00 target price (up previously from $57.00) on shares of Haemonetics in a report on Wednesday, February 7th. Morgan Stanley upped their target price on shares of Haemonetics from $74.00 to $77.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $80.00 target price on shares of Haemonetics in a report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $71.33.
ILLEGAL ACTIVITY WARNING: “California Public Employees Retirement System Has $5.69 Million Stake in Haemonetics Co. (HAE)” was published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3254753/california-public-employees-retirement-system-has-5-69-million-stake-in-haemonetics-co-hae.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.